{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:28:34Z","timestamp":1789176514244,"version":"build-2803163510"},"reference-count":58,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Von Willebrand disease (VWD) is the most common inherited bleeding disorder, resulting from deficiency or dysfunction of von Willebrand factor (VWF), a protein crucial for hemostasis. Current prophylactic options present significant limitations including poor tolerability, short half-life, or the requirement for frequent IV administration. Here, we report HMB-002, a human Fc-silenced monovalent IgG4 antibody designed to provide convenient subcutaneous prophylaxis by binding and elevating levels of endogenous VWF. Binding studies and X-ray crystallography revealed that HMB-002 binds VWF with subnanomolar affinity at a well-defined epitope in the C-terminal cysteine-knot (CK) domain, which is spatially distant from regions mediating VWF\u2019s hemostatic functions. Consistent with structural analyses, in vitro functional studies demonstrated that HMB-002-bound VWF retained its ability to bind factor VIII (FVIII), platelet GPIb\u03b1, and collagen, as well as susceptibility to proteolytic regulation by ADAMTS13. In cynomolgus monkeys, IV and subcutaneous administration of HMB-002 resulted in time-dependent accumulation of endogenous VWF and FVIII antigen, reaching about twofold elevation with a proportional increase in VWF activity and with retained VWF multimer distribution. HMB-002 also extended the half-life of coadministered recombinant VWF by approximately threefold. Using a surrogate antibody with overlapping epitope specificity, similar VWF accumulation was observed in a type 1 VWD mouse model with improved hemostasis following vascular challenge. By elevating levels of circulating VWF and FVIII, HMB-002 represents a potential subcutaneous prophylactic treatment approach to mitigate the hemostatic impairment in VWD and address current limitations in disease management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018516","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:21:06Z","timestamp":1769102466000},"page":"2551-2562","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease"],"prefix":"10.1182","volume":"10","author":[{"given":"Mattias","family":"H\u00e4ger","sequence":"first","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-7939","authenticated-orcid":false,"given":"Minka","family":"Zivkovic","sequence":"additional","affiliation":[{"name":"2Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7949-4899","authenticated-orcid":false,"given":"Prafull S.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-3588","authenticated-orcid":false,"given":"Caroline","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Bonvoisin","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rane A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Poulsen","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-5685","authenticated-orcid":false,"given":"Dana","family":"Huskens","sequence":"additional","affiliation":[{"name":"3Synapse Research Institute, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-7068","authenticated-orcid":false,"given":"Mark","family":"Roest","sequence":"additional","affiliation":[{"name":"3Synapse Research Institute, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ferrara","sequence":"additional","affiliation":[{"name":"4Specifica, An IQVIA Business, Santa Fe, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-7459","authenticated-orcid":false,"given":"Anais","family":"Naretto","sequence":"additional","affiliation":[{"name":"5SARomics Biostructures AB, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Renaud","sequence":"additional","affiliation":[{"name":"6LYO-X AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole H.","family":"Olsen","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-9264","authenticated-orcid":false,"given":"Nicolas O.","family":"Eskesen","sequence":"additional","affiliation":[{"name":"7Gubra, H\u00f8rsholm, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-6146","authenticated-orcid":false,"given":"Lars","family":"Holten-Andersen","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthvik","family":"Malladi","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Rea","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-9393","authenticated-orcid":false,"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[{"name":"2Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2899-0404","authenticated-orcid":false,"given":"Henrik","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"1Hemab Therapeutics, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"2","key":"2026041411211572400_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"10","key":"2026041411211572400_bib2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026041411211572400_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"issue":"22","key":"2026041411211572400_bib4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood.2021014729","article-title":"Structural basis of von Willebrand factor multimerization and tubular storage","volume":"139","author":"Zeng","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026041411211572400_bib5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood-2013-11-523639","article-title":"Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2026041411211572400_bib6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2026041411211572400_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","article-title":"Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis","volume":"25","author":"Stockschlaeder","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"21","key":"2026041411211572400_bib8","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.2020009197","article-title":"Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy","volume":"137","author":"Fuller","year":"2021","journal-title":"Blood"},{"issue":"5584","key":"2026041411211572400_bib9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1126\/science.107355","article-title":"Structures of glycoprotein Ib\u03b1 and its complex with von Willebrand factor A1 domain","volume":"297","author":"Huizinga","year":"2002","journal-title":"Science"},{"issue":"6","key":"2026041411211572400_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0038-1650400","article-title":"A3 domain is essential for interaction of von Willebrand factor with collagen type III","volume":"75","author":"Lankhof","year":"1996","journal-title":"Thromb Haemost"},{"issue":"21","key":"2026041411211572400_bib11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041411211572400_bib12","doi-asserted-by":"crossref","first-page":"10760296221130334","DOI":"10.1177\/10760296221130334","article-title":"Disease burden in patients with von Willebrand disease potentially eligible for prophylaxis: post hoc analysis of a European cross-sectional study","volume":"28","author":"Du","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"21","key":"2026041411211572400_bib13","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/bloodadvances.2019000368","article-title":"New therapies for von Willebrand disease","volume":"3","author":"Mannucci","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2026041411211572400_bib14","doi-asserted-by":"crossref","first-page":"e12546","DOI":"10.1002\/rth2.12546","article-title":"Tranexamic acid evidence and controversies: an illustrated review","volume":"5","author":"Relke","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"32","key":"2026041411211572400_bib15","doi-asserted-by":"crossref","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","article-title":"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent","volume":"110","author":"Merchant","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026041411211572400_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/cimm.2000.1617","article-title":"In vitro characterization of five humanized OKT3 effector function variant antibodies","volume":"200","author":"Xu","year":"2000","journal-title":"Cell Immunol"},{"issue":"7","key":"2026041411211572400_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2026041411211572400_bib18","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J Biol Chem"},{"issue":"1","key":"2026041411211572400_bib19","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41598-017-02823-9","article-title":"Efficient generation of bispecific murine antibodies for pre-clinical investigations in syngeneic rodent models","volume":"7","author":"Labrijn","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2026041411211572400_bib20","doi-asserted-by":"crossref","first-page":"1685350","DOI":"10.1080\/19420862.2019.1685350","article-title":"Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models","volume":"12","author":"Wang","year":"2020","journal-title":"mAbs"},{"issue":"1","key":"2026041411211572400_bib21","doi-asserted-by":"crossref","first-page":"1815995","DOI":"10.1080\/19420862.2020.1815995","article-title":"An accelerated surface-mediated stress assay of antibody instability for developability studies","volume":"12","author":"Kopp","year":"2020","journal-title":"mAbs"},{"issue":"4","key":"2026041411211572400_bib22","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1074\/jbc.M508191200","article-title":"Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain","volume":"281","author":"Staelens","year":"2006","journal-title":"J Biol Chem"},{"issue":"1","key":"2026041411211572400_bib23","first-page":"77","article-title":"A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels","volume":"89","author":"Federici","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"2026041411211572400_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s44161-023-00418-4","article-title":"A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders","volume":"3","author":"Gandhi","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"20","key":"2026041411211572400_bib25","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/bloodadvances.2023010643","article-title":"Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in vitro and in vivo","volume":"7","author":"Jongejan","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"2026041411211572400_bib26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa\u2013mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026041411211572400_bib27","doi-asserted-by":"crossref","first-page":"1980942","DOI":"10.1080\/19420862.2021.1980942","article-title":"Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries","volume":"13","author":"Teixeira AAR","year":"2021","journal-title":"mAbs"},{"issue":"1","key":"2026041411211572400_bib28","doi-asserted-by":"crossref","first-page":"2115200","DOI":"10.1080\/19420862.2022.2115200","article-title":"Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs","volume":"14","author":"Teixeira","year":"2022","journal-title":"mAbs"},{"issue":"2","key":"2026041411211572400_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/2472555219897567","article-title":"New advances in cell microarray technology to expand applications in target deconvolution and off-target screening","volume":"25","author":"Freeth","year":"2020","journal-title":"SLAS Discov"},{"issue":"9","key":"2026041411211572400_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"pt 4","key":"2026041411211572400_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"2","key":"2026041411211572400_bib32","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/jth.15174","article-title":"Wall shear rates in human and mouse arteries: Standardization of hemodynamics for in vitro blood flow assays: communication from the ISTH SSC subcommittee on biorheology","volume":"19","author":"Panteleev","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026041411211572400_bib33","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/ATVBAHA.112.254144","article-title":"Simultaneous exposure of sites in von Willebrand factor for glycoprotein Ib binding and ADAMTS13 cleavage: studies with ristocetin","volume":"32","author":"Chen","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2026041411211572400_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3324\/haematol.2024.286076","article-title":"A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options","volume":"110","author":"McCluskey","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2026041411211572400_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/asheducation-2009.1.106","article-title":"Low von Willebrand factor: sometimes a risk factor and sometimes a disease","volume":"2009","author":"Sadler","year":"2009","journal-title":"Hematology"},{"issue":"4","key":"2026041411211572400_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026041411211572400_bib37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler","year":"2003","journal-title":"Blood"},{"issue":"26","key":"2026041411211572400_bib38","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026041411211572400_bib39","doi-asserted-by":"crossref","first-page":"31-10","DOI":"10.1038\/s41525-023-00375-8","article-title":"Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases","volume":"8","author":"Seidizadeh","year":"2023","journal-title":"NPJ Genom Med"},{"key":"2026041411211572400_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"Von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"de Jong","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"2026041411211572400_bib41","doi-asserted-by":"crossref","first-page":"2402701","DOI":"10.1080\/19420862.2024.2402701","article-title":"Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors","volume":"16","author":"Hale","year":"2024","journal-title":"mAbs"},{"key":"2026041411211572400_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/B978-0-7020-7167-6.00002-6","volume-title":"Medical Pharmacology and Therapeutics","author":"Waller","year":"2018"},{"issue":"13","key":"2026041411211572400_bib43","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1074\/jbc.M310436200","article-title":"An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation","volume":"279","author":"Lenting","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"2026041411211572400_bib44","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2008-01-133181","article-title":"Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo","volume":"112","author":"Van Schooten","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2026041411211572400_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15565","article-title":"von Willebrand factor clearance \u2013 biological mechanisms and clinical significance","volume":"183","author":"O\u2019Sullivan","year":"2018","journal-title":"Br J Haemat"},{"issue":"13","key":"2026041411211572400_bib46","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2024024055","article-title":"The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1","volume":"144","author":"Chion","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026041411211572400_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"2026041411211572400_bib48","doi-asserted-by":"crossref","first-page":"e0124930","DOI":"10.1371\/journal.pone.0124930","article-title":"FcRn rescues recombinant factor VIII Fc fusion protein from a VWF independent FVIII clearance pathway in mouse hepatocytes","volume":"10","author":"van der Flier","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"2026041411211572400_bib49","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1074\/jbc.M117.817064","article-title":"Half-life\u2013extended recombinant coagulation factor IX\u2013albumin fusion protein is recycled via the FcRn-mediated pathway","volume":"293","author":"Chia","year":"2018","journal-title":"J Biol Chem"},{"issue":"1","key":"2026041411211572400_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026041411211572400_bib51","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin\u00ae): a prospective study of 50 patients","volume":"5","author":"Borel-derlon","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026041411211572400_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"De Wee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"3","key":"2026041411211572400_bib53","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","article-title":"Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study","volume":"21","author":"Van Galen","year":"2015","journal-title":"Haemophilia"},{"issue":"18","key":"2026041411211572400_bib54","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1182\/bloodadvances.2021006757","article-title":"Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease","volume":"6","author":"Atiq","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"2026041411211572400_bib55","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026041411211572400_bib56","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model","volume":"106","author":"Tiede","year":"2021","journal-title":"Haematologica"},{"key":"2026041411211572400_bib57","doi-asserted-by":"crossref","first-page":"20406207211064064","DOI":"10.1177\/20406207211064064","article-title":"Prophylactic management of patients with von Willebrand disease","volume":"12","author":"Franchini","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"suppl 4","key":"2026041411211572400_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14518","article-title":"Towards novel treatment options in von Willebrand disease","volume":"28","author":"Lenting","year":"2022","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2551\/2513595\/blooda_adv-2025-018516-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2551\/2513595\/blooda_adv-2025-018516-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:21:30Z","timestamp":1776180090000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2551\/566205\/HMB-002-a-monovalent-antibody-that-elevates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018516","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,14]]}}}